Participants were randomly assigned to receive Trikafta or placebo based on age and weight: Aged 6 to <12 years and less than 30kg: morning dose of elexacaftor 100mg/tezacaftor 50mg/ivacaftor 75mg ...

The majority of patients have at least one F508del mutation. TRIKAFTA's mechanism aims to correct the defective CFTR protein, improving salt and water flow in cells and alleviating symptoms.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

Trikafta, a drug approved for use in Canada in 2021 that dramatically improves the functioning of the lungs, has revolutionized treatment and significantly increased the life expectancy of people ...

Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...

generic versions of Trikafta, a particularly effective triple-combination treatment for the disease, which causes the body to produce thick, sticky mucus that damages the lungs and other organs.

The drug is also eligible for use in CF patients who have discontinued Trikafta or Vertex’s other CF medicines. Similar regulatory filings are also under review in Europe. However, the drug’s ...

The majority of patients have at least one F508del mutation. TRIKAFTA's mechanism aims to correct the defective CFTR protein, improving salt and water flow in cells and alleviating symptoms. The FDA ...